Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mirikizumab Formulations in Healthy Participants
NCT05515601Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mirikizumab in ulcerative colitis (UC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Mirikizumab at Day 85, Area Under the Concentration Versus Time Curve From Time Zero to Infinity at Day 85 and 1 more. Started Aug 2022; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05515601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515601.